EMA to revoke PIP oncology waivers, says more cancer trials needed in children
This article was originally published in Scrip
As a result of concerns that pharmaceutical companies are not conducting enough clinical trials in children, the European Medicines Agency's pediatrics committee (PDCO) is planning to revoke class waivers for paediatric investigation plans in some conditions on the grounds that the waivers are preventing the agency from requesting studies in children, especially in the field of oncology. The move would not affect drugs already on the market, unless they were submitted for review in additional indications.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-four guidance documents have been posted on the tracker since its last update.
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.